Skip to main content

AnaptysBio, Inc. (ANAB) Stock Analysis

SellVALUE-TRAP 1/5Moderate Confidence

Healthcare · Biotechnology

Sell if holding. Engine safety override at $60.48: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.3/10. Specifically: High short interest: 22%; Below-average business quality.

AnaptysBio is a clinical-stage biotech focused on autoimmune and inflammatory diseases, with lead program rosnilimab (anti-IL13, Phase 2b completed for RA) and ANB033 (Phase 1b for celiac/EoE) in its wholly owned pipeline. Revenue comes from milestones and royalties under a GSK... Read more

$60.48+21.8% A.UpsideScore 4.3/10#135 of 157 Biotechnology
QualityF-score6 / 9FCF yield0.48%
Stop $56.07Target $73.40(analyst − 13%)A.R:R 1.4:1
Analyst target$84.36+39.5%11 analysts
$73.40our TP
$60.48price
$84.36mean
$140

Sell if holding. Engine safety override at $60.48: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.3/10. Specifically: High short interest: 22%; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 4.3/10, moderate confidence.

Passes 7/9 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 77d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.

Val6.4Qual3.6Grw0.5Mom4.7Sent7.6Ins3.3Peer2.6Tech6.4Risk3.54.3OVERALL

Recent Developments — AnaptysBio, Inc.

Latest news

Generated 2026-05-20T21:06:21Z.

Thesis

Rewards
No bull case signals
Risks
Concentration risk — Pipeline: rosnilimab
Concentration risk — Counterparty: GSK
Quality below floor (3.6 < 4.0)

Key Metrics

P/E (TTM)—
P/E (Fwd)10.1
Mkt Cap$1.7B
EV/EBITDA41.9
Profit Mgn-11.5%
ROE-114.6%
Rev Growth-8.0%
Beta0.48
DividendNone
Rating analysts18

Quality Signals

Piotroski F6/9

Options Flow

P/C0.50bullish
IV139%elevated
Max Pain$40-33.9% vs spot

Concentration Risks(10-K Item 1A)

  • HIGHpipelinerosnilimab
    10-K Item 1A: 'We are assessing advancement to Phase 3 of clinical development of rosnilimab for RA, and have no history of commercializing biotechnology products'
  • HIGHcounterpartyGSK
    10-K Item 1A: 'Our existing collaboration with GSK and other collaborations are important to our business, and other future collaborations may also be important to us. If we are unable to maintain the GSK collaboration, or if this collaboration is not successful, our business could be adversely affected.'

Material Events(8-K, last 90d)

  • 2026-04-20Item 5.02LOW
    AnaptysBio completed the Spin-Off of First Tracks Biotherapeutics on April 20, 2026. Company distributed all First Tracks shares to holders; TRAX began trading on Nasdaq. Separation and transition services agreements entered into.
    SEC filing →
  • 2026-03-27Item 5.02LOW
    Board approved distribution of First Tracks Biotherapeutics shares as a spin-off dividend prior to U.S. market open on April 20, 2026. SpinCo also announced a ~$80M private placement to third-party investors at $13.81/share.
    SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

3 floor-breakers

Revenue shrinking — -8.0% YoY. Growth thesis broken unless recovery story develops.static

Revenue Growth
0.5
Declining revenue: -8%
Low model confidence on this dimension (33%).

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Quality Rank
1.7
Growth Rank
2.8
Value Rank
5.9

Unprofitable operations — net margin -11.5%. Quality floor flags this regardless of sector context.static

Roe
0.0
Net Margin
0.0
Moat
3.2
Fcf Quality
3.7
Roa
4.5
Gross Margin
4.9
Current Ratio
5.4
Piotroski F
6.7
FCF-positive but moderate margins (FCF margin 4%, FCF yield 0.5%)No competitive moat
GatesA.R:R 1.4 < 1.5@spotMomentum 4.7<5.5 (soft — BUY_NOW allowed but watch)Momentum 4.7>=4.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 77d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARSuitability: Aggressive
RSI
38 · Neutral
↓ 20D MA↑ 50D MA↑ 200D MAGOLDEN CROSSSupport $49.80Resistance $72.36

Price Targets

$56
$73
A.Upside+21.4%
A.R:R1.4:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! Quality below floor (3.6 < 4.0)
! Reward/Risk 1.4:1 at current price — below 1.5:1 minimum

Earnings

B
B
B
B
4/4 beats
Next Earnings2026-08-05 (77d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is ANAB stock a buy right now?

Sell if holding. Engine safety override at $60.48: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.3/10. Specifically: High short interest: 22%; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $56.07. Score 4.3/10, moderate confidence.

What is the ANAB stock price target?

Take-profit target: $73.40 (+21.8% upside). Prior stop was $56.07. Stop-loss: $56.07.

What are the risks of investing in ANAB?

Concentration risk — Pipeline: rosnilimab; Concentration risk — Counterparty: GSK; Quality below floor (3.6 < 4.0).

Is ANAB overvalued or undervalued?

AnaptysBio, Inc. trades at a P/E of N/A (forward 10.1). TrendMatrix value score: 6.4/10. Verdict: Sell.

What do analysts say about ANAB?

18 analysts cover ANAB with a consensus score of 4.2/5. Average price target: $84.

What does AnaptysBio, Inc. do?AnaptysBio is a clinical-stage biotech focused on autoimmune and inflammatory diseases, with lead program rosnilimab...

AnaptysBio is a clinical-stage biotech focused on autoimmune and inflammatory diseases, with lead program rosnilimab (anti-IL13, Phase 2b completed for RA) and ANB033 (Phase 1b for celiac/EoE) in its wholly owned pipeline. Revenue comes from milestones and royalties under a GSK collaboration (Jemperli/dostarlimab) and license revenue from Vanda Pharmaceuticals for imsidolimab.

Related stocks: AUPH (Aurinia Pharmaceuticals Inc) · ADMA (ADMA Biologics Inc) · HALO (Halozyme Therapeutics, Inc.) · GLPG (Galapagos NV) · HRMY (Harmony Biosciences Holdings, I)